Debbie Rigby rounds up the latest in research news
Moderate quality evidence from 10 RCT trials indicates that faecal microbiota transplantation (FMT) is more effective in patients with Clostridium difficile-associated diarrhoea (CDAD) than vancomycin or placebo. FMT was statistically significantly more effective (RR, 0.41; 95% CI, 0.22–0.74; NNT, 3; 95% CI, 2–7). The authors suggest further investigations are needed to determine the best route of administration and FMT preparation.
Med J Aust 2017; 207 (4): 1.
Published evidence suggest there is a potential role for the combination of SGLT-2 inhibitors with insulin in type 1 diabetes for improving glycaemic control without increasing the risk of hypoglycemia. All 3 SGLT-2 inhibitors (canagliflozin, empagliflozin, dapagliflozin), when combined with insulin, resulted in an overall reduction of haemoglobin A1C (up to 0.49%), lower total daily insulin doses, and a reduction in weight (up to 2.7 kg).
Annals of Pharmacotherapy. First Published May 23, 2017
This systematic review and individual patient data meta-analysis has concluded there is no good evidence to support the use of glucosamine for hip or knee OA. Glucosamine was no better than placebo for pain or function at short (3 months) and long-term (24 months) follow-up. There is also an absence of evidence to support specific consideration of glucosamine for any clinically relevant OA subgroup according to baseline pain severity, BMI, sex, structural abnormalities or presence of inflammation.
Annals of the Rheumatic Diseases 2017.
There are several reports describing enhanced anticoagulant effects when glucosamine has been taken with warfarin. There have been no reports of interaction between glucosamine and the DOACs. Glucosamine does not appear to adversely affect plasma blood glucose in patients without diabetes. Anecdotal reports suggest that adding glucosamine to a paracetamol regimen may decrease pain control in patients with osteoarthritis.
UKMI QA Glucosamine interactions update, June 17.